The Efficacy and Safety of Ferriprox for the Treatment of Transfusional Iron Overload in Patients With Sickle Cell Disease or Other Anaemias
Phase of Trial: Phase IV
Latest Information Update: 14 Nov 2019
Price : $35 *
At a glance
- Drugs Deferiprone (Primary) ; Deferoxamine
- Indications Iron overload
- Focus Therapeutic Use
- Acronyms FIRST
- Sponsors ApoPharma
- 14 Nov 2019 This trial has been discontinued in UK, according to European Clinical Trials Database record.
- 10 Jan 2019 Planned End Date changed from 1 Sep 2019 to 1 Oct 2019.
- 10 Jan 2019 Planned primary completion date changed from 1 Sep 2019 to 1 Oct 2019.